Protara Therapeutics Receives FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Lymphatic Malformations

Protara Therapeutics; TARA-002; FDA; Breakthrough Therapy; Fast Track; Lymphatic Malformations; Pediatric

Spotlight On: Five key oncology stories to watch in 2026

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology